The future of ARVs in Africa - Presentations

Previous conference information:


2nd Southern African HIV Clinicians Society (SAHCS) long-acting treatment and prevention conference: ‘The future of antiretrovirals in Africa: Long-acting agents and beyond’
Tuesday, 29 October 2024 | Johannesburg, South Africa

Conference programme - Click here
Conference presentations:
Long-acting agents - where do these products fit in the African context? | Dr Catherine Orrell
Lenacapavir, a novel capsid inhibitor for HIV treatment and prevention | Prof Francois Venter
From trial to implementation – can IMPALA help us jump across the gap? | Dr Nigel Garrett
What are the treatment options for patients with multidrug-resistant HIV-1 infection? | Dr Mohammed Rassool
What is the role of lenacapavir in future first-line HIV treatment? | Prof Francois Venter
How long-acting injectable ART could help adolescent and young adults | Dr Lauren Jennings
Pre-exposure prophylaxis in adolescent girls and young women at risk of HIV infection | Dr Nkosiphile Ndlovu
Uptake and retention of adolescents and young adults in differentiated HIV prevention | Prof Maryam Shahmanesh
LA medications: Where do they fit in for niche populations in an African context? | Prof Lee Fairlie
Long-acting PrEP in Pregnancy and Breastfeeding | Dr Dvora Joseph Davey
Advancements in Neonatal HIV Therapy | Dr Adrie Bekker
Progress towards bringing Long-acting ART to children and adolescents | Mo Archary
Assessing the demographic, risk profile, and clinical characteristics of early PrEP adopters | Dr Pippa Macdonald
PrEP LA implementation in Botswana | Dr Ava Avalos
 


1st SAHCS long-acting HIV treatment and prevention conference
20 September 2022 | Johannesburg, South Africa

Conference programme – download here
Conference presentations: